Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | ACACA | Q13085 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583289 | 0.90 | MAPK10 (0.46) | PKLRACACBACACACYP3A4CYP2C19 | |
| SCHEMBL5582973 | 0.89 | MAPK10 (0.49) | PKLRMAPK10RIPK1KDRALDH1A1 | |
| SCHEMBL5582988 | 0.88 | ACACB (0.45) | PKLRACACBACACACYP3A4GAA | |
| SCHEMBL5583155 | 0.87 | MAPK10 (0.44) | ACACBACACAMAPK10RIPK1KDR | |
| SCHEMBL5583135 | 0.86 | MAPK10 (0.48) | ACACBACACAMAPK10RIPK1KDR | |
| Sulfuric Acid SCHEMBL5583133 | 0.85 | PKLR (0.46) | PKLRACACBACACACYP3A4GAA | |
| SCHEMBL5583248 | 0.85 | MAPK10 (0.48) | PKLRACACBACACAGAAMAPK10 | |
| SCHEMBL5583184 | 0.84 | PKLR (0.46) | PKLRACACBACACACYP3A4GAA | |
| SCHEMBL5583138 | 0.84 | ACACB (0.51) | ACACBACACAMAPK10RIPK1KDR | |
| SCHEMBL5583167 | 0.84 | MAPK10 (0.46) | PKLRACACBACACAMAPK10RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | IGF1R, KDR, ERBB2 | PKLR 1931/4885ACACB 4317/4885ACACA 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.